Fellowships, Grants, & Awards by unknown
Cancer Intervention and Surveillance Modeling
Network (CISNET)
The Division of Cancer Control and Population
Sciences (DCCPS) of the National Cancer Institute
(NCI) invites applications from domestic and foreign
applicants to support collaborative research using sim-
ulation and other modeling techniques to describe the
impact of interventions in population-based settings
that will shed light on U.S. population-based trends.
It is well known that great progress in the war against
cancer is possible by the complete use and adequate
delivery of existing modalities of cancer control. The
primary goals of this research are to determine the
impact of cancer control interventions on observed
trends in incidence and/or mortality, and to deter-
mine if recommended interventions are having their
expected population impact by examining discrepan-
cies between controlled cancer intervention study
results and the population experience.
Once a general understanding of the various fac-
tors influencing current trends has been achieved, a
number of secondary goals may be addressed.
Applicants may propose secondary goals of modeling
the potential impact of new interventions on future
national trends, and/or evaluating optimal cancer con-
trol strategies.
The NCI has a long-standing function of provid-
ing answers to critical policy questions, which can
only be answered through an indirect synthesis of
available information and assumptions. A commit-
ment to modeling of this type will allow the NCI to
apply the most sophisticated tools available for evi-
dence-based planning to several areas: 1) Be respon-
sive to challenges due to the increasing pace of
technology, and to provide short-term answers while
randomized controlled trials (RCTs) are still in
progress. In the future we will be increasingly faced
with new interventions, biomarkers, and diagnostic
and genetic tests that will become widely disseminated
prior to rigorous testing in controlled settings, and
therefore the evaluation of population impact will
become even more important. 2) Address emerging
questions while they are still being debated in the pol-
icy forum. For example, new smokeless tobacco prod-
ucts are coming on the market, and modeling of their
potential impact can benefit the Federal Trade
Commission and other policy makers. 3) Translate
RCT evidence of quantities to the population setting.
4) Provide estimates of quantities that will never be
derived from RCTs. For example, half of Americans
alive today who ever smoked are ex-smokers. It is
important to understand the patterns of quitting, the
process of carcinogenesis for ex-smokers, and the
implications for future lung cancer trends.  
DCCPS, which fulﬁlls a federal-level function to
respond to evolving surveillance questions of national
policy relevance, helps focus research questions and
acts as a conduit to national data resources necessary
for parameter estimation, model calibration, valida-
tion, and population trends. An emergent property of
this collaborative agreement is progress toward a com-
prehensive understanding of the determinants of site-
specific cancer trends at the population level and a
better understanding of the science of modeling. 
Modeling is the use of mathematical and statisti-
cal techniques within a logical framework to integrate
and synthesize known biological, epidemiological,
clinical, behavioral, genetic, and economic informa-
tion. Prior to the Cancer Intervention and
Surveillance Modeling Network (CISNET), many of
the simulation and other modeling techniques had
been utilized to describe the impact of cancer inter-
ventions (i.e., primary prevention, screening, treat-
ment) for hypothetical cohorts or in trial and other
clinical settings. The goal of this request for
applications (RFA) is to promote the application and
extension of these models to population-based settings
in order to ascertain determinants of cancer trends.
This information is critical to the NCI because of the
necessity of understanding whether recommended
interventions are having their expected population
impact, and of predicting the potential impact of new
interventions on national trends. These studies will
often involve extrapolation of results of controlled
cancer intervention studies to estimates of U.S. popu-
lation and community effectiveness. This type of
modeling addresses issues of population-based policies
and programs, and is distinct from individual-level
models of risk and models of clinical decision making
used at the individual patient–physician level. An
additional goal of this concept is to advance method-
ology for modeling and to develop more uniform cri-
teria for model validation in the population setting.
It is not the purpose of this RFA to focus on the
analysis of hypothetical or trial-based cohorts and/or
cost-effectiveness analyses, but rather to support
analyses based on realistic scenarios of population
impact. Projects will focus on models describing the
population impact of the observed dissemination of
cancer control interventions as well as other factors on
observed national incidence and/or mortality trends.
CISNET was originally funded as a cooperative
agreement (U01) for two phased-in rounds of fund-
ing. In September 2000, RFA CA-99-013 funded
seven grants in breast cancer, one in prostate cancer,
and one in colorectal cancer. A second round, funded
under RFA CA-02-010 in August 2002, funded ﬁve
grants in lung cancer as well as two additional grants
for colorectal cancer and one in prostate cancer. 
CISNET investigators are currently engaged in a
wide range of policy-relevant modeling studies includ-
ing the following:
1) Development of base case questions. A major
strength of having a consortium of modelers is the
ability to employ a comparative modeling approach.
While each modeler has areas of individual focus,
whenever possible, common “base” questions have
been developed that allow for comparisons across
models. The sometimes widely different results from
models are often difficult to resolve, and base cases
provide a chance to reach consensus on important
questions, and to better understand differences
between models. In these base case questions, a set of
common population inputs is used across all models
(e.g., dissemination patterns of screening and treat-
ment, mortality from noncancer causes), and a com-
mon set of intermediate and final outputs is
developed to help understand differences and similari-
ties across models.
2) Breast base case spin-off questions. The breast
base case serves as a jumping-off point for each
grantee as they vary the basic formulation to focus on
areas of individual interest. Spin-off issues that are
actively being pursued include a) modeling the impact
of using alternative, more biologically based natural
disease history formulations, especially continuous
time tumor growth models (which include micro-
scopic fatal metastases that are initially undetectable);
b) analyses for different racial, ethnic, and insur-
ance-status groups; c) a unique Bayesian approach to
update its prior estimates of treatment efficacy to
obtain posterior estimates of community effectiveness
of adjuvant therapy and mammography that best
reproduce national mortality trends; d) geographically
based analyses; e) the role of risk factors in breast can-
cer trends; and f) the potential impact of optimal
screening intervals.
3) Prostate cancer. CISNET researchers have pub-
lished an analysis of trends in the use of the prostate-
specific antigen (PSA) test for modeling prostate
cancer incidence trends to obtain estimates of over-
diagnoses associated with PSA screening. In addition,
these researchers are investigating the use of modeling
to better understand the results of ecologic analyses of
the effectiveness of PSA screening. 
4) Special issue of Statistical Methods in Medical
Research. CISNET was invited to sponsor a special
issue of the journal Statistical Methods in Medical
Research titled “Uses of Stochastic Models for the
Early Detection of Cancer,” with articles submitted in
spring 2003. Articles in the issue include 1)
“Distribution of Clinical Covariates at Detection of
Cancer: Stochastic Modeling and Statistical
Inference,” 2) “Planning Public Health Programs and
Scheduling: Breast Cancer,” 3) “Planning of
Randomized Trials,” 4) “The Use of Modeling to
Understand the Impact of Screening on U.S.
Mortality: Examples from Mammography and PSA
Screening,” 5) “Parameter Estimation for Stochastic
Models via Simulation,” and 6) “Diversity of Model
Approaches.”
5) Linkages with other cancer surveillance and con-
trol activities. CISNET has sought linkages to be inte-
grated with and responsive to situations where
modeling may play an important role. For example,
the Agency for Health Research and Quality and the
Center for Medicare and Medicaid Studies
approached the NCI for assistance in studying a reim-
bursement decision related to the immunochemical
fecal occult blood test (iFOBT) (http://cisnet.
cancer.gov/reports/medicare.html). CISNET model-
ers have also been asked to aid in a midcourse (2005)
evaluation to help determine whether reaching
Healthy People 2010 upstream goals for cancer treat-
ment, screening, and prevention will enable us to fall
short of, meet, or exceed the downstream 2010 cancer
mortality goals, and to retarget our efforts if necessary.
This reissuance of CISNET will be limited to
modeling applications focusing on breast, prostate,
lung, and colorectal cancer. Although the reissuance
of CISNET will not be limited to grantees previously
or currently funded, CISNET will no longer fund
models that either are starting from scratch or have
not been previously applied to the analysis of popula-
tion trends. This means that models should have been
applied to multiple real birth cohorts representing the
actual population experience. Models that have been
applied only to hypothetical cohorts, as is sometimes
done to model trial data or estimate cost-effectiveness,
will not be considered. The emphasis in this reis-
suance is in the application of already developed mod-
els to study the population impact of existing or
emerging cancer control interventions. In addition,
applications are being solicited for cancer site–speciﬁc
coordinating centers for breast, prostate, colorectal,
and lung cancer.
Areas of application will include more refined
analyses of current trends, and a renewed emphasis on
future trends and optimal cancer control planning.
While the original issuance focused primarily on dis-
covery (basic mathematical and statistical relationships
necessary for the development of multi-cohort popu-
lation models) and development (data sources and
realistic scenarios to evaluate past intervention impact
in the population setting and project future impact),
the reissuance will continue development efforts and
will greatly enhance the delivery element (synthesizing
relevant scenarios for informing policy decisions and
cancer control planning implementation).
While some new mathematical and statistical
derivations may be necessary, they should not be the
centerpiece of these applications. Instead, the focus of
the application should be on identifying important
cancer surveillance and control questions, obtaining
the data sources and making model modiﬁcations as
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are meaningful and packaged in a way that policy
makers and cancer control planners can understand.
Inclusion of interdisciplinary expertise will be essential
in this phase of CISNET. Applicants should demon-
strate modeling capability and propose a specific
research plan. However, applicants should be ﬂexible
enough to accommodate further reﬁnement and inte-
gration with other efforts.
The purpose of these efforts is to model the
impact of the observed dissemination of cancer con-
trol interventions in the population, rather than using
observed population trends to postulate new etiologic
factors. However, these models can include compo-
nents that model the impact of population changes in
both modifiable and nonmodifiable risk factors.
Models that include the synergistic impact of multiple
interventions simultaneously are desirable. Models
can be of the entire U.S. population, a region of the
country, some specific identified population where
unique data exist on the implementation of an inter-
vention, or in a subpopulation of specific interest
(e.g., the rural poor). However, whenever possible,
inference should relate to the United States as a
whole. Models can be developed for non-U.S. popula-
tions, but should be justiﬁed based on their applicabil-
ity to understanding U.S. cancer trends. 
Examples of areas of interest and types of ques-
tions are given below. Note that these are examples
only, and applicants should not feel constrained to
choose areas of application from this list only.  
1) What new quantifiable statements can be
made concerning estimates and uncertainty in the
adenoma-colorectal cancer sequence? What is the
range of natural history models associated with in
situ breast cancer, and what are the implications of
these natural history models for the overdiagnosis of
disease?
2) What is the contribution of treatment to
observed declines in prostate cancer mortality, espe-
cially the transition from the use of androgen depriva-
tion therapy after biochemical failure (i.e., rising PSA
levels) to use in the adjuvant setting? How can future
improvements in the quality of care and the general
health status of older individuals result in increased
use and responsiveness to treatment? 
3) What is the impact on incidence and mortal-
ity of both the increased dissemination of currently
established screening modalities (e.g., iFOBT, sig-
moidoscopy) and the potential dissemination of new
or more novel modalities (e.g., screening
colonoscopy, advanced imaging modalities, iFOBT,
fecal mutagen tests, other innovative biomarkers)? As
screening trial results for PSA, flexible sigmoi-
doscopy, chest X ray, and spiral computed tomogra-
phy start to become available over the next decade,
how do these results alter our understanding of popu-
lation trends in incidence and mortality? 
4) Given that obesity is a major problem that is
getting worse, what are the implications for projec-
tions of breast and colorectal cancer mortality? What
is the expected dissemination of the use of tamoxifen
for women with different risk proﬁles, and what is the
projected mortality reduction associated with these
levels of dissemination?  
5) How would resource requirements be affected
by the use of risk stratiﬁcation models or biomarkers
that would allow selective screening and/or selective
surveillance monitoring of higher-risk individuals?
What is the national burden of iatrogenic morbidity
from prostate cancer treatment among screen-
detected men, and how do we weigh this against the
potential mortality gains?
6) Can we use population trends to better under-
stand differences in the natural history of prostate
cancer between white and black men, and how can we
use this information to better target interventions?
How do racial disparities in obesity impact future
trends? What is the impact of racial, economic, and
insurance-status disparities in the use of adjuvant ther-
apy and mammography on breast cancer mortality? 
7) What is the impact of changing Medicare
reimbursement policies on screening, treatment, and
cancer mortality?
8) CISNET models should be able to help
translate (in a timely manner) the impact of speciﬁc
emergent results from epidemiologic, genetic, treat-
ment, prevention, and screening studies to the popu-
lation setting. Recent examples include how the
mutation of a gene involved in non–small cell lung
cancer increases the likelihood that the drug geﬁtinib
will show a beneficial response; how a prevention
trial showed that although finasteride reduced the
risk of developing prostate cancer, those who devel-
oped the cancer had higher-grade tumors; and how
an international clinical trial found that post-
menopausal survivors of early-stage breast cancer
who took the drug letrozole after completing an ini-
tial five years of tamoxifen therapy had a signifi-
cantly reduced risk of cancer.
9) CISNET models can help translate the rela-
tionship between upstream (e.g., screening, modifi-
able risk factors) and downstream (e.g., mortality)
goals. It can also help target the upstream factors that
have the most potential for inﬂuencing mortality. In
addition, CISNET models can help target what types
of emerging technologies have the largest potential to
help us reach the NCI’s 2015 goal of eliminating suf-
fering from cancer. Is enough known about these
technologies to have conﬁdence in these projections?
Can modeling point to the most important studies
that could be conducted to gain more conﬁdence with
respect to their operating characteristics?
In the ﬁrst issuance of CISNET no funds were
speciﬁcally allocated for coordination activities. In this
reissuance we have set aside funds for coordinating
centers for all four cancer sites: breast, prostate, col-
orectal, and lung cancer. Coordinating centers should
be site-speciﬁc because each center needs to be totally
conversant with the data sources, modeling issues, and
policy questions specific to that cancer site.
Coordination activities, under the general direction
and consensus of the NCI and principal investigators,
will include 1) formulating, prioritizing, and coordi-
nating work on base case and other questions (includ-
ing outside requests); 2) negotiating common requests
for outside data sources; 3) consensus building and
coordinating critical evaluation of disparate results; 4)
preparing inputs, and collecting and processing com-
mon outputs for model comparisons; and 5) coordi-
nating synthesis papers and group responses, bringing
together disparate information to inform policy mak-
ers. Through the coordinating center, each CISNET
cancer site group will constitute an established expert
knowledge base that can provide technical advice on
evolving policy-relevant surveillance questions.
Because all of the expertise necessary to accomplish
these goals is not likely to exist in one place, the coor-
dinating center would have discretionary funds to tap
outside expertise for particular tasks, pay for access to
data sources, and provide funds to modeling groups to
mount intensive efforts to provide technical advice
while issues are still relevant in the policy area. Even
though one group would be tasked with being the
coordinating center, CISNET would be run through
consensus, as it has in the past.
To keep applications focused, each will be lim-
ited to a single cancer site. The CISNET project
requirements call for the development of site-speciﬁc
working groups that will 1) facilitate comparative
analyses, 2) allow modeling groups access to a broader
array of data resources and interdisciplinary expertise,
and 3) provide a forum for discussions of validation
and other methodologic issues. CISNET will allow
for diversity and originality of modeling approaches
that can be compared using uniform criteria. New
investigators will be expected to join in the ongoing
collaborative activities already under way.  
The NCI intends to commit approximately
$1.8 million in total costs (direct and facilities and
administrative [F&A] costs) in fiscal year 2005 to
fund 6–9 new modeling grants in response to this
RFA. In addition, the NCI intends to commit
approximately $950,000 (direct and F&A costs) in
ﬁscal year 2005 to fund 4 coordinating centers (one
each in breast, prostate, colorectal, and lung cancer).
An applicant may request a project period of up to
ﬁve years. Although an applicant can submit applica-
tions for more than one cancer site (either for model-
ing grants or coordinating centers), each individual
application must be limited to one cancer site.
Coordinating center grants must be submitted sepa-
rately from modeling grants, even if one applicant
submits both. 
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 1-
866-705-5711 or through the website at http://www.
dunandbradstreet.com/. The DUNS number should
be entered on line 11 of the face page of the PHS 398
form. The PHS 398 document is available at
http://grants.nih.gov/grants/funding/phs398/phs398.
html in an interactive format. For further assistance,
contact GrantsInfo by calling 301-435-0714 or e-
mailing GrantsInfo@nih.gov.
Letters of intent must be received by 14
September 2004. Applications must be received by
14 October 2004. The anticipated award date is
July 2005.
Contact: Eric Feuer, DCCPS, NCI, 6116
Executive Blvd, Rm 5041, MSC 8317, Bethesda, MD
20892-8317 USA, 301-496-5029, fax: 301-480-
2046, e-mail: rf41u@nih.gov. Reference: RFA No.
RFA-CA-05-018
Defender of the Earth Book Award
Red Hen Press announces the ﬁrst annual Defender
of the Earth Book Award to promote awareness and
appreciation of the need to respect the beauty and
fragility of the environment. This award is for a pre-
viously unpublished original manuscript of nonfic-
tion writing on the environment, and is open to all
authors. The award is to be presented by the David
Family Foundation.
The winner will receive $5,000 and publication
of the winning manuscript by Red Hen Press. The
minimum page count for submissions is 64 pages.
The author’s name should appear only on the cover
sheet. Send a self-addressed stamped envelope for
notification. Entries must be postmarked by 30
August 2004.
Contact: Red Hen Press, Attention: Defender
of the Earth Book Award, PO Box 3537, Granada
Hills, CA 91394 USA, 818-831-0649, e-mail: 
editors@redhen.org, Internet: http://www.redhen.org/
2004literaryawards.htm
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